AGP Executive Report
Last update: 2 hours agoNovartis: The FDA expanded remibrutinib’s US use to adults with symptomatic dermographism, a form of chronic hives that can be triggered by friction. In a trial, 29.3% of patients had complete hive resolution after 12 weeks, versus 14% on placebo. Cancer Care: A Dutch court ordered MSD to stop selling its injectable Keytruda formulation in eight European markets, including Switzerland, over a patent dispute. Ebola Response: Roche is supplying laboratory equipment to support Ebola testing in the Democratic Republic of Congo. Swiss Health Costs: Health insurance premiums are rising again, with ageing only part of the explanation, according to a recent report. Research and Treatment: A review drawing on more than 1.3 million adults in Austria, Germany, Italy and Switzerland linked chronic insomnia with higher risks of stroke, hospital admission and other serious health outcomes. Swiss biotech MUVON also reported positive 12-month follow-up results for its investigational muscle-regeneration therapy for stress urinary incontinence.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
